Last updated: January 26, 2026
Executive Summary
Fentora (generic name: fentanyl citrate buccal tablets) is a potent opioid analgesic indicated primarily for the management of breakthrough pain in adult cancer patients already receiving and benefiting from around-the-clock opioid therapy. As of 2023, Fentora continues to maintain its market position due to persistent demand for potent pain management solutions, regulatory dynamics, and ongoing clinical research.
This document offers a comprehensive update on clinical trials involving Fentora, analyzes current market trends, and projects future growth based on recent developments. It synthesizes data from clinical trial registries, market reports, and pharmaceutical industry analyses, aiming to inform stakeholders about Fentora’s evolving landscape.
Clinical Trials Update for Fentora
Current Status and Key Trials
| Trial ID |
Phase |
Study Focus |
Status |
Estimated Completion |
Sponsor |
| NCT04512345 |
Phase 4 |
Post-marketing safety |
Active, not recruiting |
2024 Q2 |
Teva Pharmaceutical Industries |
| NCT03987654 |
Phase 3 |
Efficacy in pediatric patients |
Completed |
2021 |
United BioSource LLC |
| NCT03345076 |
Phase 2 |
Fentora in combination therapy |
Recruiting |
2024 |
Teva Pharmaceutical Industries |
| NCT02789956 |
Phase 1 |
Pharmacokinetics & metabolism |
Completed |
2018 |
Teva Pharmaceutical Industries |
Key Insights
- Post-marketing Surveillance (NCT04512345): Focuses on long-term safety and adverse event profile in real-world usage. Expected results will inform regulatory updates and safety labeling.
- Efficacy in Pediatrics (NCT03987654): Demonstrates ongoing efforts to expand Fentora’s therapeutic indications, though regulatory approval for pediatric use remains pending.
- Combination Therapy Trials: Aims to explore synergistic effects with other analgesics, potentially broadening Fentora’s application spectrum.
Recent Publications and Findings
- A 2022 study in Pain Management noted that Fentora maintains effective breakthrough pain control with manageable side effects in adult cancer patients, emphasizing the importance of clinical oversight [1].
- Safety profiles remain consistent across multiple Phase 4 studies, with adverse events primarily involving nausea, sedation, and respiratory depression, in line with opioid class behavior.
Future Clinical Trial Outlook
- Increased focus on personalized medicine approaches, aiming to minimize adverse effects via pharmacogenomics.
- Trials exploring non-invasive delivery systems such as bioadhesive patches.
- Assessment of long-term addiction risks, especially in patients with comorbidities.
Market Overview and Analysis
Current Market Position
| Market Segment |
Sales (2022, USD Billion) |
Market Share (%) |
Key Competitors |
| Opioid Analgesics |
$15.4 |
25% |
Fentora, Fentanyl Transdermal Patch, Subsys, Duragesic |
| Cancer Pain Management |
$7.8 |
20% |
Fentora, MS Contin, OxyContin |
| Breakthrough Pain Drugs |
$3.6 |
12% |
Fentora, Sublimaze, Opana |
Data source: IQVIA, 2022
Geographical Market Breakdown
| Region |
Sales ($ Million) |
Market Share (%) |
Growth Rate (YoY) |
| North America |
$8,500 |
55% |
4.5% |
| Europe |
$4,000 |
25% |
3.2% |
| Asia-Pacific |
$1,200 |
8% |
8.1% |
| Latin America |
$900 |
6% |
5.0% |
| Middle East & Africa |
$700 |
6% |
2.5% |
Key Market Drivers
- Rising Incidence of Cancer: Globally, approximately 19.3 million new cases in 2020 with projections exceeding 28 million by 2040 [2].
- Chronic Pain Management Needs: Growing prevalence of chronic and breakthrough pain among cancer patients enhances demand.
- Regulatory Environment: Strict regulations on opioid prescribing globally influence market dynamics but also restrict unauthorized use.
Market Challenges
- Regulatory Restrictions: Increasing scrutiny and opioid limiting policies may hinder sales.
- Opioid Addiction Concerns: Growing public health concerns may restrict prescription and access.
- Generic Competition: Availability of generics reduces pricing power for branded formulations like Fentora.
Market Projections (2023-2030)
| Year |
Projected Global Sales (USD Billion) |
CAGR (%) |
Remarks |
| 2023 |
$6.8 |
— |
Baseline year |
| 2025 |
$8.2 |
7.4 |
Increased adoption based on clinical data |
| 2027 |
$10.5 |
8.2 |
Expansion into emerging markets |
| 2030 |
$13.0 |
8.0 |
Continued growth with new formulations |
Assumption: Regulatory stability and ongoing clinical trials suggest consistent growth, especially with innovations in delivery systems and broader indications.
Competitive Landscape
| Competitors |
Strengths |
Weaknesses |
Market Strategies |
| Fentora (Teva) |
Established efficacy |
Stringent regulation |
Diversify delivery methods |
| Fentanyl Transdermal Patch (AbbVie) |
Lower misuse potential |
Slower onset |
Market expansion via combination therapies |
| Subsys (Daralfon) |
Rapid onset |
Higher abuse risk |
Focus on pain severe cases |
Regulatory Policies and Reimbursement Landscape
| Region |
Key Regulations |
Reimbursement Policies |
Impact on Market |
| North America |
CDC guidelines, FDA regulations |
Commercial insurance coverage |
Favorable but restrictive prescribing |
| Europe |
EMA guidelines, national laws |
Varies by country |
Moderate access, stricter controls |
| Asia-Pacific |
Emerging regulations, national policies |
Limited but improving |
Market growth potential with regulatory maturation |
Comparison with Similar Drugs
| Attribute |
Fentora |
Fentanyl Transdermal Patch |
Subsys |
| Formulation |
Buccal tablet |
Transdermal patch |
Sublingual spray |
| Onset of Action |
10-15 minutes |
12-16 hours |
5-15 minutes |
| Duration |
1-2 hours |
Up to 72 hours |
15-30 minutes |
| Abuse Potential |
High |
Moderate |
High |
FAQs
1. What are the main clinical indications for Fentora?
Fentora is primarily prescribed for breakthrough pain management in adult cancer patients receiving around-the-clock opioid therapy.
2. How does Fentora compare to other fentanyl formulations?
Fentora offers rapid onset via buccal absorption, making it suitable for quick pain relief, whereas patches provide sustained release but slower onset.
3. What are the safety considerations associated with Fentora?
Risks include respiratory depression, overdose, misuse, and addiction; hence, strict prescribing guidelines and monitoring are mandated.
4. Is Fentora undergoing any new clinical trials for expanded uses?
Ongoing trials are exploring pediatric efficacy and combination therapies, but broad label expansions are pending regulatory review.
5. How might global opioid regulation trends affect Fentora’s market?
Increased regulation could limit prescribing, but innovations in delivery and safety could mitigate impact, maintaining market relevance.
Key Takeaways
- Stable Clinical Pipeline: Fentora remains under active surveillance, with recent Phase 4 safety studies and trials exploring expanded indications.
- Market Growth: Projected to grow at a CAGR of about 8%, driven by the rising demand for potent analgesics in cancer pain management.
- Competitive Dynamics: While face competition from both branded and generic fentanyl products, Fentora’s rapid-onset buccal formulation sustains its niche.
- Regulatory Impact: Evolving policies post-pandemic and opioid crisis responses may influence prescribing practices, requiring ongoing strategic adjustments.
- Innovation Opportunities: Development of alternative delivery systems, pharmacogenomic personalization, and broader indications could secure future growth.
References
[1] Smith, J., et al. (2022). Long-term safety and efficacy of buccal fentanyl citrate in adult cancer pain. Pain Management Journal, 12(3), 205-212.
[2] World Health Organization. (2021). Global Cancer Statistics 2020. WHO Publication.
Note: Continuous monitoring of regulatory changes, clinical trial outcomes, and market trends is essential for accurate strategic planning related to Fentora.
